If you are unable to view this e-mail, click here to view it online.
Overview
Today’s rough economic climate is having a dramatic impact on the funding of small pharma and biotech companies. Top executives in the industry are asking such questions as:
n How do I choose the right strategic path?
n What are the opportunities and risks associated with various strategies?
n How do I prepare for partnership, outsourcing, or sale?
n What is the most cost-effective way to ensure the maximum value of my IP?
n How do I get to my next milestone with limited time and money?
n Am I missing out on opportunities outside the U.S.?
This joint seminar, presented by Dechert’s Life Sciences Practice and The Weinberg Group, will present creative strategies to help small companies survive and thrive in these cash-lean times. Attendees will benefit from the speakers’ collective insights, while informally networking with peers who are facing similar challenges.
When and Where
Thursday, December 11, 2008
8:00 AM – 10:30 AM
Dechert LLP
1775 I Street, NW
Washington, D.C. 20006-2401
8:00 AM – 8:30 AM
Breakfast and registration
8:30 AM – 10:30 AM
Program
RSVP: Robyn Ross
By phone: +1 215 994 6751
By e-mail: robyn.ross@dechert.com
By web: www.dechert.com/seminars
There is no fee to attend, but seminar space is limited. When you register, please include your name, title, company name, address, and e-mail address.
Please respond by Friday,
December 5, 2008.
Program
Innovative Regulatory Strategies and Development Plans
Joel Falk
Executive Vice President
The Weinberg Group
Topics will include:
n The leveraged impact of regulatory strategy and development plans on the cost, duration, and success of development
n Increasing the efficiency of clinical trials
n Maximizing value and return from partnership or outsourcing transactions
In Search of Cash: Collaborations, Outlicensing, M&A Sales, and Financing Alternatives
David E. Schulman
Partner
Dechert LLP
Topics will include:
n When and how collaborations, outlicensing, and M&A sales become attractive options
n Unorthodox financing techniques (when PIPES and private placement equity rounds are unavailable)—rights offerings, standby equity lines, whole company secured debt transactions, convertible debt and preferred stock transactions, and royalty stream sales transactions
n The opportunities and challenges posed by global transactions
IP Considerations in the Current Economic Climate
Daniel M. Becker, M.D.
Partner
Dechert LLP
Topics will include:
n Looking beyond the immediate funding crisis—understanding IP timelines
n Geographic considerations
n Cost-effectively managing FTO risks
About Dechert’s Life Sciences Practice
Recognized as a leading adviser worldwide by PLC Global 2007 Life Sciences Super League and Chambers Global, Dechert LLP advises many of the world’s largest pharmaceutical, medical device, and biotechnology companies. The firm’s distinguished trial team—including one of the top product liability practices in the nation—defends clients in consumer fraud investigations and lawsuits, high-stakes product liability and securities fraud class actions, infringement litigation, and licensing disputes. Our business lawyers help new and established companies prosper by advising them on growth strategies, including financings, M&A transactions, and corporate partnering, while our intellectual property lawyers find smart and creative ways to maximize and protect our clients’ assets.
About The Weinberg Group
For more than 25 years, The Weinberg Group has helped our life sciences clients bring their products to market by providing innovative clinical, regulatory, and compliance strategies. As a multinational scientific and regulatory consulting firm, our FDA and EMEA experts offer comprehensive guidance and support throughout all phases of a product’s life cycle.
